doi: 10.4178/epih.e2014009, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 27.Yang YJ, Kim MK, Hwang SH, Ahn Y, Shim JE, Kim DH
(Gross spending does not account for any rebates paid by drug manufacturers to pharmacy benefit managers, which would result in lower net Medicare spending.) Gross spending on Ozempic alone increased from $2.6 billion in 2021 to $4.6 billion in 2022, pushing it to 6th place among the top-selling drugs in Medicare Part D that year, up from 10th place the year before
Drug-induced GR inhibition : Several medications, including antimalarials, antipsychotics, and certain chemotherapeutic agents, can inhibit GR activity
The first follow-up review is usually at week four to six
Medical appropriateness varies by patient